Company Analysis
Sign in

Vertex Pharmaceuticals Incorporated (VRTX)

Nasdaq: VRTX · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 1995
Full chart Alerts Compare
Grade7.0
◀ Past 7.3● Present 7.6▶ Future 5.9
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

1,313 patents granted to the 9 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Vertex Pharmaceuticals Incorporated’s names, not what it holds today.

Patents granted
1,313
1,283 utility, 24 design, 6 reissue, 1976 to Dec 31, 2025
Granted in 2025
47
Against 40 in 2024 and 33 in 2023
Applications published
1,245
71 of them in 2025
Names they are printed under
9
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals80
Organic fine chemistry55
Biotechnology36
Medical technology15
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name9 counted
Vertex Pharmaceuticals Incorporated its own name
US, as the owner printed on each patent. 2 more under the same name are not counted (printed in GB)
1,155 granted
750 published
Vertex Pharmaceuticals Incorporated its own name
named as the applicant on its applications, in US. 1 more under the same name are not counted (printed in MA)
0 granted
334 published
ViaCyte, Inc. a subsidiary
US, as the owner printed on each patent
109 granted
72 published
ALPINE IMMUNE SCIENCES, INC. a subsidiary
US, as the owner printed on each patent
25 granted
44 published
ViaCyte, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
26 published
Vertex Pharmaceuticals (San Diego) LLC a subsidiary
US, as the owner printed on each patent
19 granted
3 published
Vertex Pharmaceuticals (Europe) Limited a subsidiary
GB, as the owner printed on each patent
5 granted
5 published
Vertex Pharmaceuticals (Europe) Limited a subsidiary
named as the applicant on its applications, in GB
0 granted
7 published
Alpine Immune Sciences, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
4 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,508,231Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acidPharmaceuticalsVertex Pharmaceuticals Incorporated
Dec 23, 202512,503,439Heteroaryl compounds for the treatment of painOrganic fine chemistryVertex Pharmaceuticals Incorporated
Dec 23, 202512,502,376Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)PharmaceuticalsVertex Pharmaceuticals Incorporated
Dec 16, 202512,497,614Compositions and methods for editing beta-globin for treatment of hemaglobinopathiesBiotechnologyVertex Pharmaceuticals Incorporated
Dec 9, 202512,492,388Materials and methods for treatment of hemoglobinopathiesBiotechnologyVertex Pharmaceuticals Incorporated
Dec 2, 202512,486,312Immunomodulatory proteins with tunable affinitiesPharmaceuticalsALPINE IMMUNE SCIENCES, INC.
Nov 4, 202512,458,635Pharmaceutical composition and administrations thereofPharmaceuticalsVertex Pharmaceuticals Incorporated
Oct 14, 202512,442,020Materials and methods for treatment of pain related disordersBiotechnologyVertex Pharmaceuticals Incorporated
Oct 14, 202512,441,703Carboxamides as modulators of sodium channelsOrganic fine chemistryVertex Pharmaceuticals Incorporated
Oct 14, 202512,440,481Esters and carbamates as modulators of sodium channelsOrganic fine chemistryVertex Pharmaceuticals Incorporated
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388543HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAINPharmaceuticalsVertex Pharmaceuticals Incorporated
Dec 25, 20252025/0388541HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAINOrganic fine chemistryVertex Pharmaceuticals Incorporated
Dec 11, 20252025/0376462ISLET CELL MANUFACTURING COMPOSITIONS AND METHODS OF USEPharmaceuticalsVertex Pharmaceuticals Incorporated
Dec 4, 20252025/03669703-DIMENSIONAL LARGE CAPACITY CELL ENCAPSULATION DEVICE ASSEMBLYMedical technologyViaCyte, Inc.
Nov 27, 20252025/0361211DEUTERATED CFTR POTENTIATORSOrganic fine chemistryVertex Pharmaceuticals (Europe) Limited
Nov 20, 20252025/0353836N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELSOrganic fine chemistryVertex Pharmaceuticals Incorporated
Nov 20, 20252025/0353834PROCESS FOR THE SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN MODULATORS OF SODIUM CHANNELSOrganic fine chemistryVertex Pharmaceuticals Incorporated
Nov 6, 20252025/0340574MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOROrganic fine chemistryVertex Pharmaceuticals Incorporated
Nov 6, 20252025/0340568SOLID FORMS OF A MACROCYCLIC COMPOUNDS AS CFTR MODULATORS AND THEIR PREPARATIONOrganic fine chemistryVertex Pharmaceuticals Incorporated
Oct 30, 20252025/0332151METHODS OF TREATMENT FOR CYSTIC FIBROSISPharmaceuticalsVertex Pharmaceuticals Incorporated
What it applied for, 2024 to 2025: Pharmaceuticals 49 · Biotechnology 35 · Organic fine chemistry 29 · Medical technology 10 · Analysis of biological materials 1 · Surface technology, coating 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton VRTX · research, not advice